| **Statement of Deficiencies** | **(X1) Provider/Supplier/CLIA Identification Number**<br><br>46D0707201 | **(X3) Date Survey Completed**<br><br>11/23/2021 |
|---|---|---|
| **Name of Provider or Supplier**<br><br>Arthritis Clinic Of Central Utah | **Street Address, City, State**<br><br>3650 N University Ave Ste 150, Provo, UT | |
| For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency. | | |

| **(X4) ID Prefix Tag** | **Summary Statement of Deficiencies** |
|---|---|
| **D2016** | SUCCESSFUL PARTICIPATION<br>CFR(s): 493.803(a)(b)(c)<br><br>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.<br><br>This CONDITION is not met as evidenced by:<br>Based on American Proficiency Institute (API) performance summary review and confirmation by API on 11/23/2021, the laboratory failed to achieve successful participation in two consecutive events for Total Bilirubin proficiency testing performance. (See D2096). The laboratory conducts approximately 97,500 routine chemistry and urinalysis test annually. |
| **D2096** | ROUTINE CHEMISTRY<br>CFR(s): 493.841(f) |

| | |
|---|---|
| | Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.<br><br>This STANDARD is not met as evidenced by:<br>Based on American Proficiency Institute (API) performance summary review and confirmation by API on 11/23/2021, the laboratory failed to achieve successful participation in two consecutive events for Total Bilirubin (TBil) proficiency testing performance. The laboratory conducts approximately 97,500 routine chemistry and urinalysis test annually. Findings include: 1. API summary report included documentation that the laboratory failed TBil in two consecutive events (second event of 2021 and third event of 2021 of Routine Chemistry evaluation) with scores of 60% and 40% respectively. 2. API records were reviewed online via the API website on 11 /23/2021 to verify the test results of 60% for the second event of 2021 and 40% for the third event of 2021. |